• +353-1-416-8900(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)
MediPoint: Bioabsorbable Stents - US Analysis and Market Forecast - Product Image

MediPoint: Bioabsorbable Stents - US Analysis and Market Forecast

  • Published: December 2012
  • Region: United States
  • 134 pages
  • GlobalData

FEATURED COMPANIES

  • Abbott Vascular
  • Amaranth Medical
  • Arterius
  • Biotronik SE & Co. KG
  • OrbusNeich
  • REVA Medical, Inc.
  • MORE

MediPoint: Bioabsorbable Stents - US Analysis and Market Forecast

Summary

GlobalData has released its medical device report, MediPoint: Bioabsorbable Stents - US Analysis and Market Forecast. The report is a vital source of up-to-date information with in-depth analysis on the Bioabsorbable Stent (BAS) Market in the US. Provided within is a comprehensive breakdown of opportunities and inhibitors within the US BAS market, highlighting testimonials from physicians from around the world utilizing this technique already. Currently, Bioabsorbable Stents have not received regulatory approval and are not available for sale in the US. The report identifies and analyzes the key trends that will drive the US Bioabsorbable Stent market in the future. The US sales expectations are discussed through careful analysis of Bioabsorbable Stent implantation procedure adoption patterns. The report provides insight into the competitive BAS landscape in the US, including new companies entering the market and pipeline products in development. This report is built using data and information sourced from proprietary databases, primary and secondary and in-house analysis by Our team of industry READ MORE >

1
1

1.1 List of Tables
1.2 List of Figures
2 Introduction
2.1 Catalyst
2.2 Related Reports
3 Disease Overview
3.1 Coronary Artery Disease
3.2 Peripheral Artery Disease
3.3 Anatomy and Physiology
3.4 Pathophysiology
3.4.1 Coronary Artery Disease
3.4.2 Peripheral Artery Disease
3.5 Clinical Presentation
3.5.1 Symptoms of Coronary Artery Disease (NHLBI, 2011c)
3.5.2 Symptoms of Peripheral Artery Disease (Stoppler, 2012)
3.5.3 Risk Factors
3.5.4 Disease Segments
3.5.5 Diagnosis
3.6 Clinical Outcomes
3.6.1 Treatment Paradigm
3.6.2 Treatment Modalities
3.6.3 Coronary/Peripheral Artery Bypass Grafting
3.6.4 Interventional Cardiology
3.7 Epidemiology
3.7.1 Coronary Artery Disease
3.7.2 Peripheral Artery Disease
3.8 Economic Impact
3.8.1 Coronary Artery Disease
3.8.2 Peripheral Artery Disease
3.8.3 Treatment Costs
4 Competitive Assessment
4.1 Overview
4.2 Absorb BVS - Abbott Vascular
4.2.1 Efficacy
4.2.2
4.2.3 SWOT Analysis
4.3 Remedy - Kyoto Medical Planning
4.3.1 Efficacy
4.3.2 SWOT Analysis
5 Unmet Needs
5.1 Biodegradable and Bioabsorbable Stents
5.2 Reduce Risk of Complications
5.3 Reduce the Need for Stent-in-Stent Procedures
5.4 Long-Term Clinical Data
5.5 Stent Fracture
5.6 Dual Anti-Platelet Therapy
5.7 Imaging
6 Pipeline Products
6.1 Overview
6.2 Pipeline by Phases in Development - Coronary Artery Disease
6.3 Pipeline Product Profiles - Coronary Artery Disease
6.3.1 Igaki-Tamai Stent
6.3.2 ReZolve Sirolimus Eluting Bioabsorbable Coronary Scaffold
6.3.3 Drug-Eluting Absorbable Metal Scaffold
6.3.4 Absorbable Metal Stents
6.3.5 DESolve Bioabsorbable Coronary Scaffold System
6.3.6 ART Stent
6.3.7 The OrbusNeich Stent
6.3.8 TephaFLEX Absorbable Stent
6.3.9 The Arterius Stent
6.3.10 Zorion Medical Stent
6.3.11 3V Avatar
6.3.12 Biosorb
6.3.13 Summary
6.4 Pipeline by Phases in Development - Peripheral Artery Disease
6.5 Pipeline Product Profiles- Peripheral Artery Disease
6.5.1 Magic Explorer Stent
6.5.2 Esprit Bioabsorbable Vascular Scaffold
6.5.3 ART Stent
6.5.4 TephaFLEX Absorbable Peripheral Stent
6.5.5 Zorion Medical Stent
6.5.6 Amaranth Medical Stent
6.5.7 Summary
6.6 Clinical Trial Analysis
6.6.1 Overview
6.6.2 Trials to Watch
7 Industry Overview
7.1 Procedure Trends
7.1.1 Factors Contributing to Rise of Coronary and Peripheral Interventions
7.1.2 Coronary Artery Disease
7.1.3 Peripheral Artery Disease
7.2 Market Access
7.2.1 United States
7.3 Reimbursement Trends
7.3.1 United States
7.4 Regulatory Issues/Recalls
8 Current and Future Players
8.1 Overview
8.2 Trends in Corporate Strategy
8.3 Company Profiles
8.3.1 Abbott Vascular
8.3.2 Kyoto Medical Planning Co., Ltd
8.3.3 Biotronik SE & Co. KG
8.3.4 REVA Medical, Inc.
8.3.5 Elixir Medical Corporation
8.3.6 Arterial Remodeling Technologies
8.3.7 Tepha, Inc.
8.3.8 OrbusNeich
8.3.9 Arterius
8.3.10 Zorion Medical
8.3.11 S3V Vascular Technologies
8.3.12 ICON Interventional Systems
8.3.13 Amaranth Medical
8.3.14 Medlogics Device Corporation
9 Market Drivers, Opportunities and Barriers
9.1 Market Drivers
9.1.1 Rising Prevalence of Disease
9.1.2 Avoid Stent-in-Stent Procedures
9.1.3 Reduce/Eliminate Dual Anti-Platelet Therapy
9.1.4 Availability of Long-Term Data
9.1.5 Treatment Cost Considerations
9.1.6 Accurate Stent Placement
9.1.7 Expected Launch of Bioabsorbable Stents in the US
9.2 Opportunities
9.2.1 Bioabsorbable Stent Market Segmentation
9.2.2 Expand Indications of Bioabsorbable Stenting
9.2.3 Target High-Risk Patients
9.2.4 Improve Deliverability of Bioabsorbable Stents
9.2.5 Emerging Markets
9.3 Market Barriers
9.3.1 Slow Adoption
9.3.2 Complications with Bioabsorbable Stents
9.3.3 High Selling Price
9.3.4 Reimbursement
9.3.5 Substitutes
10 Country Outlooks and Forecasts
10.1 US Market Overview
10.2 United States
10.2.1 Overview
10.2.2 Market Analysis
11 Appendix
11.1 Bibliography
11.2 Abbreviations
11.3 Report Methodology
11.3.1 Overview
11.3.2 Coverage
11.3.3 Secondary Research
11.3.4 Forecasting Methodology
11.4 Physicians and Specialists Included in this Study
11.5 Physician Survey
11.6 About the Authors
11.6.1 Analysts
11.6.2 Global Head of Healthcare
11.7 About MediPoint
11.8 About Us
11.9 Contact Us
11.10 Disclaimer

1.1 List of Tables
Table 1: Risk Factors Associated with Coronary Artery Disease
Table 2: Risk Factors Associated with Peripheral Artery Disease
Table 3: Types of Coronary Artery Bypass Grafting
Table 4: Drugs Incorporated into Drug-Eluting Stents
Table 5: Prevalence of CAD in =65 population in the US, millions
Table 6: Prevalence of PAD Among =65 Population in the US, millions
Table 7: Description of Direct and Indirect Economic Costs
Table 8: Economic Impact ($bn) of CAD in the US
Table 9: Economic Impact ($bn) of PAD in the US-
Table 10: US Hospital Charges for Interventional Cardiology Procedures
Table 11: Marketed Bioabsorbable Stent Products
Table 12: Absorb BVS Product Portfolio
Table 13: Absorb BVS SWOT Analysis, 2012
Table 14: Remedy Stent Product Portfolio
Table 15: Remedy SWOT Analysis, 2012
Table 16: BAS Product Pipeline (Coronary)
Table 17: Igaki-Tamai Stent SWOT Analysis, 2012
Table 18: ReZolve Stent SWOT Analysis, 2012
Table 19: DREAMS SWOT Analysis, 2012
Table 20: AMS SWOT Analysis, 2012
Table 21: BAS Product Pipeline (Peripheral)
Table 22: Magic Explorer Stent SWOT Analysis, 2012
Table 23: Esprit BVS SWOT Analysis, 2012
Table 24: Medicare National Average of Inpatient Hospital Payment for Cardiology Procedures, 2011-2012
Table 25: Company Profile - Abbott Vascular
Table 26: Marketed Bioabsorbable Stent Products by Abbott Vascular
Table 27: Pipeline Bioabsorbable Stent Products by Abbott Vascular
Table 28: Abbott Vascular SWOT Analysis, 2012
Table 29: Company Profile - Kyoto Medical Planning
Table 30: Marketed Bioabsorbable Stent Products by Kyoto Medical Planning
Table 31: Pipeline Bioabsorbable Stent Products by Kyoto Medical Planning
Table 32: Kyoto Medical Planning SWOT Analysis, 2012
Table 33: Company Profile - Biotronik
Table 34: Pipeline Bioabsorbable Stent Products by Biotronik
Table 35: Biotronik SWOT Analysis, 2012
Table 36: Company Profile - REVA Medical
Table 37: Pipeline Bioabsorbable Stent Products by REVA Medical
Table 38: REVA Medical SWOT Analysis, 2012
Table 39: Company Profile - Elixir Medical Corporation
Table 40: Pipeline Bioabsorbable Stent Products by Elixir Medical Corporation
Table 41: Elixir Medical Corporation SWOT Analysis, 2012
Table 42: Company Profile - Arterial Remodeling Technologies
Table 43: Pipeline Bioabsorbable Stent Products by Arterial Remodeling Technologies
Table 44: Arterial Remodeling Technologies SWOT Analysis, 2012
Table 45: Company Profile - Tepha
Table 46: Pipeline Stent Products by Tepha
Table 47: Tepha SWOT Analysis, 2012
Table 48: Company Profile - OrbusNeich
Table 49: Pipeline Bioabsorbable Stent Products by OrbusNeich
Table 50: OrbusNeich SWOT Analysis, 2012
Table 51: Company Profile - Arterius
Table 52: Arterius SWOT Analysis, 2012
Table 53: Company Profile - Zorion Medical
Table 54: Zorion Medical SWOT Analysis, 2012
Table 55: Company Profile - S3V Vascular Technologies
Table 56: S3V Vascular Technologies SWOT Analysis, 2012
Table 57: Company Profile - ICON Interventional Systems
Table 58: ICON Interventional Systems SWOT Analysis, 2012
Table 59: Company Profile - Amaranth Medical
Table 60: Amaranth Medical SWOT Analysis, 2012
Table 61: Company Profile - Medlogics Device Corporation
Table 62: Medlogics Device Corporation SWOT Analysis, 2012
Table 63: Bioabsorbable Stent Sales ($m) Forecast for the United States, 2011-2018
Table 64: Physicians Surveyed, By Country

1.2 List of Figures
Figure 1: Anatomy of the Human Heart
Figure 2: Pathophysiology of Coronary Artery Disease
Figure 3: Pathophysiology of Peripheral Artery Disease
Figure 4: Treatment Modalities - Coronary Artery Disease
Figure 5: Interventional Cardiology Procedures for Treating CAD, US and Europe, 2012
Figure 6: Treatment Modalities - Peripheral Artery Disease
Figure 7: Interventional Cardiology for Treating PAD, US and Europe, 2012
Figure 8: Types of Stents
Figure 9: Prevalence of CAD in Population =65 Years in the US
Figure 10: Percent of Patients (=65 years) Treated for CAD, US and Europe
Figure 11: Prevalence of PAD in Population =65 Years in the US
Figure 12: Direct and Indirect Costs ($bn) of CAD in the US
Figure 13: Total Costs ($bn) of PAD in the US
Figure 14: US Hospital Charges for Interventional Procedures, 2011-2018
Figure 15: Importance of a Biodegradable and Absorbable Stent to Physicians in the US (n=20)
Figure 16: Percent of Patients with CAD Patients Experiencing Complications after Drug-Eluting Stenting, 2012 (n=10)
Figure 17: Percent of Patients with PAD Patients Experiencing Complications after Drug-Eluting Stenting, 2012 (n=10)
Figure 18: Percent of Patients (= 65 years) with CAD Receiving Stent-in-Stent Procedures, 2012 (n=10)
Figure 19: BAS Coronary Pipeline by Stage in Clinical Development, 2012
Figure 20: BAS Peripheral Pipeline by Stage in Clinical Development, 2012
Figure 21: Population (= 65 years) of CAD Patients Receiving Interventional Procedures in the US
Figure 22: Population (= 65 years) of PAD Patients Receiving Interventional Procedures in the US
Figure 23: Likelihood of Physicians Adopting Bioabsorbable Stents in the United States, 2012 (n=20)
Figure 24: Medicare National Average of Outpatient Hospitalization Payment for Interventional Cardiology Procedures, 2011-2012
Figure 25: National Medicare Average Payment for Drug-Eluting Stent Procedures for the Following Years
Figure 26: Kyoto Medical Planning Co., Ltd. Sales Volume ($m), May 2002-May 2012
Figure 27: US Bioabsorbable Stent Market ($m), 2011-2018

Abbott Vascular
Kyoto Medical Planning Co., Ltd
Biotronik SE & Co. KG
REVA Medical, Inc.
Elixir Medical Corporation
Arterial Remodeling Technologies
Tepha, Inc.
OrbusNeich
Arterius
Zorion Medical
S3V Vascular Technologies
ICON Interventional Systems
Amaranth Medical
Medlogics Device Corporation

Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos